Literature DB >> 16275194

Effect of sildenafil on cardiac performance in patients with heart failure.

Kozo Hirata1, Audrey Adji, Charalambos Vlachopoulos, Michael F O'Rourke.   

Abstract

Sildenafil is rarely used in patients with heart failure despite a high prevalence of erectile dysfunction, and the theoretic possibility that by increasing nitric oxide availability, it may improve left ventricular (LV) load and performance. This study aimed to determine the peak effects of sildenafil on LV load and performance in patients with heart failure caused by systolic LV dysfunction. Twenty patients with controlled LV failure and ejection fractions <35% received sildenafil 50 mg or a matching placebo when not receiving regular medication for > or =12 hours, in a randomized, placebo-controlled, double-blind, 2-way crossover fashion. Cardiac output was measured by Doppler echocardiography. The aortic pressure waveform was determined using generalized transfer function from radial artery applanation tonometry. Aortic and femoral arterial stiffness was determined as carotid-femoral and femoral-pedal pulse-wave velocity (PWV); wave reflection was measured as an augmentation index (AIx). Cardiac index increased significantly (by 0.37 L/min.m(2), p <0.0001), with the peak effect 60 minutes after sildenafil administration. Compared with the baseline value, total systemic resistance showed a reduction of 479 dynes.s.cm(-5) (p <0.0001). Aortic and lower limb PWV decreased significantly (by 0.89 and 1.14 m/s, respectively, p <0.0001 for both), as did AIx (by 3.6% absolute, p <0.0001); these remained significant after adjustment for mean pressure and heart rate changes. In conclusion, sildenafil improves cardiac performance because of a decrease in LV load, which is caused by decreases in peripheral resistance, in aortic and large artery stiffness, and in wave reflection from peripheral sites. This can explain the increase in cardiac output and in exercise capacity with sildenafil in patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275194     DOI: 10.1016/j.amjcard.2005.06.091

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

Review 1.  Clinical appraisal of arterial stiffness: the Argonauts in front of the Golden Fleece.

Authors:  C Vlachopoulos; K Aznaouridis; C Stefanadis
Journal:  Heart       Date:  2005-12-09       Impact factor: 5.994

2.  Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis.

Authors:  Andrea Sansone; Giulia Rastrelli; Angelo Cignarelli; Maurizio de Rocco Ponce; Rosita Angela Condorelli; Elisa Giannetta; Elisa Maseroli; Sara Pinto; Ciro Salzano; Daniele Santi
Journal:  Int J Impot Res       Date:  2019-06-24       Impact factor: 2.896

3.  Aortic augmentation index is associated with the ankle-brachial index: a community-based study.

Authors:  Mahyar Khaleghi; Iftikhar J Kullo
Journal:  Atherosclerosis       Date:  2007-01-24       Impact factor: 5.162

4.  Sildenafil exposure and hemodynamic effect after Fontan surgery.

Authors:  Robert D Tunks; Piers C A Barker; Daniel K Benjamin; Michael Cohen-Wolkowiez; Gregory A Fleming; Matthew Laughon; Jennifer S Li; Kevin D Hill
Journal:  Pediatr Crit Care Med       Date:  2014-01       Impact factor: 3.624

Review 5.  Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence.

Authors:  Maya Guglin
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 6.  Role of sGC-dependent NO signalling and myocardial infarction risk.

Authors:  Jana Wobst; Thorsten Kessler; Tan An Dang; Jeanette Erdmann; Heribert Schunkert
Journal:  J Mol Med (Berl)       Date:  2015-03-04       Impact factor: 4.599

Review 7.  Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Authors:  Sevil Korkmaz-Icöz; Tamás Radovits; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

8.  Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo.

Authors:  Asger Andersen; Jan M Nielsen; Sivagowry Rasalingam; Erik Sloth; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2013-12-05       Impact factor: 3.017

Review 9.  Sildenafil and phosphodiesterase-5 inhibitors for heart failure.

Authors:  Marco Guazzi
Journal:  Curr Heart Fail Rep       Date:  2008-06

Review 10.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

Authors:  H Al-Ameri; R A Kloner
Journal:  Int J Impot Res       Date:  2009-04-23       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.